<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3863">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04536051</url>
  </required_header>
  <id_info>
    <org_study_id>COV003</org_study_id>
    <nct_id>NCT04536051</nct_id>
  </id_info>
  <brief_title>A Study of a Candidate COVID-19 Vaccine (COV003)</brief_title>
  <official_title>A Randomized, Controlled, Phase III Study to Determine the Safety, Efficacy, and Immunogenicity of the Non-Replicating ChAdOx1 nCoV-19 Vaccine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Oxford</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized, Controlled, Phase III Study to Determine the Safety, Efficacy, and&#xD;
      Immunogenicity of the Non-Replicating ChAdOx1 nCoV-19 Vaccine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There will be 2 study groups and an anticipated enrolment of 10,300 health professionals and&#xD;
      adults with high potential for exposure to SARS-CoV-2, aged ≥18 years.&#xD;
&#xD;
      All subjects will undergo follow-up for a total of 1 year post last vaccination. Additional&#xD;
      visits or procedures may be performed at the discretion of the investigators, e.g., further&#xD;
      medical history and physical examination, or additional blood tests and other investigations&#xD;
      if clinically relevant&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2, 2020</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the efficacy of ChAdOx1 nCoV-19 vaccine against COVID-19 disease confirmed with PCR</measure>
    <time_frame>12 months post final vaccination</time_frame>
    <description>COVID-19 virologically confirmed symptomatic cases (PCR positive).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the safety, tolerability and reactogenicity profile of ChAdOx1 nCoV-19 candidate vaccine: occurrence of signs and symptoms of local and systemic reactogenicity requested during 7 days after vaccination</measure>
    <time_frame>7 days post vaccination</time_frame>
    <description>Occurrence of signs and symptoms of local and systemic reactogenicity requested during 7 days after vaccination (in a subset of 200 participants)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the safety, tolerability and reactogenicity profile of ChAdOx1 nCoV-19 candidate vaccine: occurrence of serious adverse events</measure>
    <time_frame>12 months post final vaccination</time_frame>
    <description>Occurrence of serious adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the safety, tolerability and reactogenicity profile of ChAdOx1 nCoV-19 candidate vaccine: occurrence of episodes; intensified disease</measure>
    <time_frame>12 months post final vaccination</time_frame>
    <description>Occurrence of episodes; intensified disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the efficacy of ChAdOx1 nCoV-19 candidate vaccine against severe and non-severe COVID-19 disease: hospitalization for COVID-19 disease confirmed by PCR</measure>
    <time_frame>12 months post final vaccination</time_frame>
    <description>Hospitalization for COVID-19 disease confirmed by PCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the efficacy of ChAdOx1 nCoV-19 candidate vaccine against severe and non-severe COVID-19 disease: COVID-19 serious disease confirmed by PCR</measure>
    <time_frame>12 months post final vaccination</time_frame>
    <description>COVID-19 serious disease confirmed by PCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the efficacy of ChAdOx1 nCoV-19 candidate vaccine against severe and non-severe COVID-19 disease: death associated with COVID-19 disease</measure>
    <time_frame>6 months</time_frame>
    <description>Death associated with COVID-19 disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the efficacy of ChAdOx1 nCoV-19 candidate vaccine against severe and non-severe COVID-19 disease: antibodies against SARS-CoV-2 non-Spike protein (serum efficacy rates)</measure>
    <time_frame>12 months post final vaccination</time_frame>
    <description>Antibodies against SARS-CoV-2 non-Spike protein (serum efficacy rates).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the humoral immunogenicity of ChAdOx1 nCoV-19: antibodies against the SARS-CoV-2 spike protein (serum conversion rates)</measure>
    <time_frame>12 months post final vaccination</time_frame>
    <description>Antibodies against the SARS-CoV-2 spike protein (serum conversion rates)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the humoral immunogenicity of ChAdOx1 nCoV-19: virus neutralizing antibodies (NAb) against live and/or pseudotyped SARS-CoV-2 virus</measure>
    <time_frame>12 months post final vaccination</time_frame>
    <description>Virus neutralizing antibodies (NAb) against live and/or pseudotyped SARS-CoV-2 virus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the cellular immunogenicity of ChAdOx1 nCoV-19 candidate vaccine</measure>
    <time_frame>12 months post final vaccination</time_frame>
    <description>Interferon-gamma (IFN-γ) enzyme-linked immunospot (ELISpot) responses to SARS-CoV-2 spike protein</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">10300</enrollment>
  <condition>Coronavirus</condition>
  <arm_group>
    <arm_group_label>Group 1a: single dose ChAdOx &amp; paracetamol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single standard dose of ChAdOx1 nCOV19 vaccine plus paracetamol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1b: single dose MenACWY &amp; paracetamol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive a single dose of MenACWY plus paracetamol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1c: two dose ChAdOx &amp; paracetamol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive two standard doses of ChAdOx1 nCoV-19 vaccine, 4-12 weeks apart, plus paracetamol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1d: two dose MenACWy/saline &amp; paracetamol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive MenACWY prime, and Saline Placebo boost (0.5mL) plus paracetamol</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ChAdOx1 nCoV-19 single dose + paracetamol</intervention_name>
    <description>Single dose of ChAdOx1nCOV19 vaccine, 5x10^10 vp + paracetamol</description>
    <arm_group_label>Group 1a: single dose ChAdOx &amp; paracetamol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MenACWY single dose + paracetamol</intervention_name>
    <description>Single dose of MenACWY + paracetamol</description>
    <arm_group_label>Group 1b: single dose MenACWY &amp; paracetamol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ChAdOx1 nCoV-19 two dose + paracetamol</intervention_name>
    <description>Two dose of ChAdOx1 nCoV-19 vaccine, 5x10^10vp (prime) and 0.5mL boost (3.5 - 6.5 × 10^10 vp), 4-12 weeks apart + paracetamol</description>
    <arm_group_label>Group 1c: two dose ChAdOx &amp; paracetamol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MenACWY prime &amp; saline placebo boost + paracetamol</intervention_name>
    <description>MenACWY prime, and Saline Placebo boost (0.5mL) + paracetamol</description>
    <arm_group_label>Group 1d: two dose MenACWy/saline &amp; paracetamol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults from 18 to 55 years of age&#xD;
&#xD;
          -  Adults aged 56-69 years old (after review of safety data by DSMB in this age group in&#xD;
             the UK trial)&#xD;
&#xD;
          -  Adults aged 70 and above years old (after review of safety data by DSMB in this age&#xD;
             group in the UK trial)&#xD;
&#xD;
          -  Able and willing (in the Investigator's opinion) to fulfill all study requirements;&#xD;
&#xD;
          -  Health professionals and adults at high risk of exposure to SARS-CoV-2, as defined in&#xD;
             section 5.2 of this protocol;&#xD;
&#xD;
          -  Serology with SARS-CoV-2 negative IgG antibodies; This inclusion criteria does not&#xD;
             apply to participants enrolled from version 4.0 of the protocol onwards.&#xD;
&#xD;
          -  Willing to allow investigators to discuss the participant's clinical history with&#xD;
             their GP/personal physician and access medical records relevant to the study&#xD;
             procedures&#xD;
&#xD;
          -  Only for women of childbearing age willing to practice continuous effective birth&#xD;
             control (see below) during the study, and a negative pregnancy test on the screening&#xD;
             and vaccination day(s);&#xD;
&#xD;
          -  Consent to abstain from blood donation during the course of the study;&#xD;
&#xD;
          -  Provide informed consent in writing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participation in trials of prophylactic drugs for COVID-19 during the course of the&#xD;
             study; Note: Participation in COVID-19 treatment trials is permitted in case of&#xD;
             hospitalization due to COVID-19, after confirmation of positive PCR. The study team&#xD;
             should be informed as soon as possible. Participants with COVID-19 not hospitalized&#xD;
             with positive PCR results for COVID-19 may be medicated according to standard clinical&#xD;
             practice.&#xD;
&#xD;
          -  Participation in SARS-CoV-2 serological research where participants are informed of&#xD;
             their serological status during the course of the study;&#xD;
&#xD;
          -  Planned receipt of any vaccine (authorized or investigational), within 30 days before&#xD;
             and after vaccination;&#xD;
&#xD;
          -  Prior receipt of an investigational vaccine or authorized with the possibility of&#xD;
             impacting the interpretation of the study data (for example, vaccines vectorized by&#xD;
             Adenovirus, any vaccines against coronavirus);&#xD;
&#xD;
          -  Administration of immunoglobulins and/or any blood products in the three months prior&#xD;
             to the planned administration of the candidate vaccine;&#xD;
&#xD;
          -  Any confirmed or suspected immunosuppressive or immunodeficiency state; asplenia;&#xD;
             severe recurrent infections and chronic use (more than 14 days) of immunosuppressive&#xD;
             medication in the last 6 months, except for topical steroids or short-term oral&#xD;
             steroids (cycle lasting ≤14 days);&#xD;
&#xD;
          -  History of allergic disease or reactions possibly exacerbated by any component of&#xD;
             ChAdOx1 nCoV-19 or MenACWY or paracetamol;&#xD;
&#xD;
          -  Any history of angioedema;&#xD;
&#xD;
          -  Any history of anaphylaxis;&#xD;
&#xD;
          -  Pregnancy, lactation or willingness/intention to become pregnant during the study;&#xD;
&#xD;
          -  Current diagnosis or treatment for cancer (except basal cell carcinoma of the skin and&#xD;
             cervical carcinoma in situ);&#xD;
&#xD;
          -  History of severe psychiatric illness that possibly affects your participation in the&#xD;
             study;&#xD;
&#xD;
          -  Hemorrhagic disorder (for example, factor deficiency, coagulopathy or platelet&#xD;
             disorder), or a previous history of significant bleeding or bruising after IM&#xD;
             injections or venipuncture;&#xD;
&#xD;
          -  Current suspected or known dependence on alcohol or drugs;&#xD;
&#xD;
          -  Severe and/or uncontrolled cardiovascular diseases, respiratory diseases,&#xD;
             gastrointestinal diseases, liver disease, kidney disease, endocrine disorder, and&#xD;
             neurological disease (mild/moderate well-controlled comorbidities are allowed);&#xD;
&#xD;
          -  History of COVID-19 confirmed by laboratory;&#xD;
&#xD;
          -  Seropositive for antibodies to SARS-CoV-2 before recruitment; This exclusion criteria&#xD;
             does not apply to participants enrolled from version 4.0 of the protocol onwards&#xD;
&#xD;
          -  Continued use of anticoagulants, such as coumarins and related anticoagulants (for&#xD;
             example, warfarin) or new oral anticoagulants (for example, apixaban, rivaroxaban,&#xD;
             dabigatran and edoxaban);&#xD;
&#xD;
          -  Any other significant illness, disorder or finding that may significantly increase the&#xD;
             risk for the participant, affect his/her ability to participate in the study or impair&#xD;
             the interpretation of the study data.&#xD;
&#xD;
        Re-vaccination exclusion criteria (two-dose groups only)&#xD;
&#xD;
          -  Anaphylactic reaction following administration of vaccine&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Pollard, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oxford</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Volunteer Recruitment Coordinator</last_name>
    <phone>01865 611424</phone>
    <email>vaccinetrials@ndm.ox.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Instituto D'Or de Pesquisa e Ensino - I'Dor</name>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <zip>41253-190</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ana Verena Mendes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro de Pesquisas Clinicas de Natal (CPCLIN)</name>
      <address>
        <city>Natal</city>
        <state>Rio Grande Do Norte</state>
        <zip>59025-050</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eveline Pipolo Milan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eduardo Sprinz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universidade Federal de Santa Maria (UFSM)</name>
      <address>
        <city>Santa Maria</city>
        <state>Rio Grande Do Sul</state>
        <zip>97105-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alexandre Vargas Schwarzbold</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto D'Or de Pesquisa e Ensino - I'Dor</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>22281-100</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ana Maria Pitella de Souze Leite</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CRIE, Universidade Federal de São Paulo</name>
      <address>
        <city>São Paulo</city>
        <zip>04038-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lily Weckx</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 1, 2020</study_first_submitted>
  <study_first_submitted_qc>September 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 2, 2020</study_first_posted>
  <last_update_submitted>November 23, 2020</last_update_submitted>
  <last_update_submitted_qc>November 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Covid-19</keyword>
  <keyword>ChAdOx1 nCov19</keyword>
  <keyword>sars-cov-2</keyword>
  <keyword>vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

